Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed

Clinical trial NCT07674368 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07674368
Sponsor: Hunan Cancer Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

ALK Fusion-positive Non-small Cell Lung Cancer

Start date: 2026-07-10
Primary completion: 2028-07-10
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.